Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
Mepolizumab and tezepelumab were associated with the greatest reductions in asthma exacerbations among patients with moderate to severe, uncontrolled asthma with nasal polyps, when compared with placebo.